Anti-inflammatory and anti-fibrotic effects of sirolimus on bleomycin-induced pulmonary fibrosis in rats

Basit Öğe Kaydı
dc.contributor.authorTulek, Baykal
dc.contributor.authorKiyan, Esen
dc.contributor.authorToy, Hatice
dc.contributor.authorKiyici, Aysel
dc.contributor.authorNarin, Cuneyt
dc.contributor.authorSuerdem, Mecit
dc.date.accessioned2020-03-26T18:13:47Z
dc.date.available2020-03-26T18:13:47Z
dc.date.issued2011
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractPurpose: Pulmonary fibrosis is a devastating disease with a poor prognosis. Although the diagnosis and pathophysiology of this disease have been better characterized over the past few years, there is no effective therapy for the disease. The aim of this study was to evaluate the anti-inflammatory and anti-fibrotic effects of sirolimus (SRL), which is a potential anti-fibrotic agent, by using bleomycin (BLM)-induced pulmonary fibrosis model in rats. Methods: A single intra-tracheal injection of BLM (2.5 U/kg) was administered and sirolimus (2.5 mg/kg/day) was given orally, beginning either one day before (early SRL) or nine days after (late SRL) the BLM administration. The effect of SRL on fibrosis was studied by analysis of cytokine levels in BAL fluid, measurement of lung tissue hydroxyproline (HPL) content and histopathological examination. Results: Both early and late SRL administrations caused a decrease in the levels of IL-13, PDGF-A and TGF-beta 1 (p=0.001) and an increase in IFN-beta levels (p=0.001) in BAL fluid. Early and late SRL also caused a decrease in HPL content (p=0.001). Early sirolimus caused a significant decrease in fibrosis score (p=0.001), while late SRL did not. Conclusion: Sirolimus was effective in BLM-induced pulmonary fibrosis model, especially in the early phases of the disease.en_US
dc.description.sponsorshipSelcuk UniversitySelcuk University [08401111]en_US
dc.description.sponsorshipThis work was support by a Scientific Research grant from Selcuk University's (Grant number: 08401111). Rapamune (Sirolimus) was supplied by Wyeth Pharmaceuticals Inc. The authors thank Dr. Aysu Kiyan for statistical analysis of the study.en_US
dc.identifier.endpageE348en_US
dc.identifier.issn0147-958Xen_US
dc.identifier.issn1488-2353en_US
dc.identifier.issue6en_US
dc.identifier.pmid22129924en_US
dc.identifier.startpageE341en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/26144
dc.identifier.volume34en_US
dc.identifier.wosWOS:000297727400007en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCANADIAN SOC CLINICAL INVESTIGATIONen_US
dc.relation.ispartofCLINICAL AND INVESTIGATIVE MEDICINEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.titleAnti-inflammatory and anti-fibrotic effects of sirolimus on bleomycin-induced pulmonary fibrosis in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu